INSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BSCQ', 'STOCK', 'Invesco BulletShares 2026 Corporate Bond ETF', 'NGM', NULL, NULL, 'The fund generally will invest at least 80% of its total assets in securities that comprise the underlying index. The underlying index seeks to measure the performance of a portfolio of U.S. dollar-denominated investment grade corporate bonds with maturities or, in some cases, "effective maturities" in the year 2026 (collectively, "2026 Bonds").', '', NULL);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ALNY', 'STOCK', 'Alnylam Pharmaceuticals, Inc.', 'NMS', 'Healthcare', 'Biotechnology', 'A Alnylam Pharmaceuticals, Inc. É uma empresa biofarmacêutica de estágio comercial. A empresa está envolvida na descoberta, desenvolvimento, fabricação e comercialização de novas terapias baseadas na interferência do ácido ribonucleico (RNAi). Seus produtos comercializados incluem AMVUTTRA (vutrisiran) para o tratamento da amiloidose mediada por transtiretina hereditária (hATTR) com polineuropatia em adultos; ONPATTRO (patisiran) para o tratamento da polineuropatia da amiloidose 1 Os programas de desenvolvimento clínico da empresa incluem Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran e ALN-HTT02. Está desenvolvendo o Cemdisiran para tratar doenças mediadas por complemento.', 'Cambridge, MA, United States', 2230);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CANF', 'STOCK', 'Can-Fite BioPharma Ltd.', 'ASE', 'Healthcare', 'Biotechnology', 'Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company''s lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific for', 'Ramat Gan, , Israel', 5);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BAK', 'STOCK', 'Braskem S.A.', 'NYQ', 'Basic Materials', 'Chemicals', 'A Braskem SA é uma petroquímica integrada no Brasil para a primeira e segunda geração de resinas termoplásticas. As atividades da Companhia são divididas em três segmentos operacionais: Brasil; Estados Unidos e Europa; e México. O segmento Brasil está focado na produção de resinas de polietileno (PE), polipropileno (PP) e policloreto de vinilo (PVC), além de insumos químicos básicos como etileno, propileno, butadieno, benzeno, tolueno, etc. cloro, soda e solventes, entre outros. O segmento Estados Unidos e Europa é responsável pela produção de polipropileno em unidades nos Estados Unidos e na Alemanha. O segmento México consiste na operação de blocos de etileno e de polietileno localizados no México.', 'São Paulo, SP, Brazil', NULL);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CTKB', 'STOCK', 'Cytek Biosciences, Inc.', 'NMS', 'Healthcare', 'Medical Devices', 'Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.', 'Fremont, CA, United States', 688);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BIAF', 'STOCK', 'bioAffinity Technologies, Inc.', 'NCM', 'Healthcare', 'Diagnostics & Research', 'bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Companys product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a persons sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.', 'San Antonio, TX, United States', 57);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ACRS', 'STOCK', 'Aclaris Therapeutics, Inc.', 'NMS', 'Healthcare', 'Biotechnology', 'Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).', 'Wayne, PA, United States', 61);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BEEM', 'STOCK', 'Beam Global', 'NCM', 'Technology', 'Solar', 'Beam Global is a clean technology innovator which develops and manufactures sustainable infrastructure products and technologies. The Company develops designs, engineers, manufactures, and sells renewably energized infrastructure products for electric vehicle (EV) charging. It also manufactures steel structures with electronic integration such as street lighting, cell towers and energy infrastructure products, as well as power electronics including invertors, charge controllers, power supplies and light-emitting diode (LED) lighting. Its product offerings include EV ARC Electric Vehicle Autonomous Renewable Charger, Solar Tree Direct Current Fast Charge (DCFC), EV ARC DCFC, BeamSpot, BeamBike, BeamPatrol, BeamWell, and UAV ARC. Its EV ARC Electric Vehicle Autonomous Renewable Charger is a patented infrastructure product that uses integrated solar power and battery storage to provide a mounting asset and a source of power for factory installed electric vehicle charging stations.', 'San Diego, CA, United States', 245);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ANNX', 'STOCK', 'Annexon, Inc.', 'NMS', 'Healthcare', 'Biotechnology', 'Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.', 'Brisbane, CA, United States', 106);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CRC', 'STOCK', 'California Resources Corporation', 'NYQ', 'Energy', 'Oil & Gas E&P', 'California Resources Corporation is an independent energy and carbon management company committed to energy transition. The Companys segments include Oil and Natural Gas and Carbon Management. Its Carbon Management business, Carbon TerraVault, focuses on building, installing, operating, and maintaining carbon dioxide (CO2) equipment, transportation assets and storage facilities. The Oil and Natural Gas segment explores for, develops and produces crude oil, oil condensate, natural gas liquids and natural gas. It has operations in oil and gas basins, including San Joaquin Basin, Los Angeles Basin, Sacramento Basin, and other. It has interests in oil and gas fields throughout the San Joaquin basin, including in Elk Hills, Buena Vista, Coles Levee, North Belridge and South Belridge, Kern Front, Lost Hills, Cymric, McKittrick, Midway Sunset and Coalinga. The Los Angeles Basin is a northwest-trending plain about 50 miles long and 20 miles wide.', 'Long Beach, CA, United States', 1550);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('EHC', 'STOCK', 'Encompass Health Corporation', 'NYQ', 'Healthcare', 'Medical Care Facilities', 'Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.', 'Birmingham, AL, United States', 28678);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ACET', 'STOCK', 'Adicet Bio, Inc.', 'NGM', 'Healthcare', 'Biotechnology', 'Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.', 'Boston, MA, United States', 152);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CISO', 'STOCK', 'CISO Global Inc.', 'NCM', 'Technology', 'Software - Infrastructure', 'CISO Global, Inc. is a cybersecurity, compliance, and software company. The Company provides a full range of cybersecurity consulting and related services, encompassing compliance, cybersecurity, and culture. It offers three types of services to clients, including security managed services, professional services, and cybersecurity software. The Companys services include managed security, compliance services, security operations center (SOC) services, virtual Chief Information Security Officer (vCISO) services, incident response, certified forensics, technical assessments, and cybersecurity training. Its cybersecurity software offers a comprehensive suite of proactive cybersecurity software solutions designed to protect organizations from evolving cyber threats. Its CISO Edge is an artificial intelligence (AI) -driven cloud security solution that provides comprehensive protection across cloud-first, hybrid, and remote environments.', 'Scottsdale, AZ, United States', 141);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('AMPY', 'STOCK', 'Amplify Energy Corp.', 'NYQ', 'Energy', 'Oil & Gas E&P', 'Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, exploitation and production of oil and natural gas properties. The Companys operations are focused on Oklahoma, the Rockies (Bairoil), federal waters offshore Southern California (Beta), and East Texas / North Louisiana. Its liquid-rich acreage in Oklahoma consisted of approximately 95 thousand net (112 thousand gross) prospective acres in the Mississippian Lime trend in the Woods and Alfalfa Counties of Oklahoma. Its liquids-heavy Rockies properties include wells and properties primarily located in the Lost Soldier and Wertz fields in the Rockies at its Bairoil complex. Its Beta properties include two wellbore production platforms and one production handling and processing platform. The Companys business activities are conducted through Amplify Energy Operating LLC, its wholly owned subsidiary, and its wholly owned subsidiaries.', 'Houston, TX, United States', 229);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ENR', 'STOCK', 'Energizer Holdings, Inc.', 'NYQ', 'Industrials', 'Electrical Equipment & Parts', 'Energizer Holdings, Inc. is a manufacturer and distributor of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance products. The Company''s segments include Batteries & Lights, and Auto Care. The Company offers household batteries including primary, rechargeable, specialty and hearing aid using many technologies including lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide. It offers auto care products in the appearance, fragrance, performance, and air conditioning recharge product categories. Its portfolio of brands includes Energizer, Armor All, Eveready, Rayovac, STP, Varta, A/C Pro, Refresh Your Car!, California Scents, Driven, Bahama & Co., LEXOL, Eagle One, Nu Finish, Scratch Doctor, and Tuff Stuff. It distributes its products to consumers through numerous retail locations worldwide, including mass merchandisers and warehouse clubs, food, drug and convenience stores, e-commerce and military stores.', 'Saint Louis, MO, United States', 5600);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CRL', 'STOCK', 'Charles River Laboratories International, Inc.', 'NYQ', 'Healthcare', 'Diagnostics & Research', 'Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.', 'Wilmington, MA, United States', 18700);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BOTZ', 'STOCK', 'Global X Robotics & Artificial Intelligence ETF', 'NGM', NULL, NULL, 'The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence as defined by Indxx, the provider of the underlying index. The fund is non-diversified.', '', NULL);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('DOX', 'STOCK', 'Amdocs Limited', 'NMS', 'Technology', 'Software - Infrastructure', 'A Amdocs Limited é uma fornecedora de software e serviços para empresas de comunicação e mídia em países desenvolvidos e mercados emergentes. As ofertas da empresa são baseadas em uma mistura de produtos e serviços, usando tecnologias e metodologias, como nuvem e nuvem nativa, microsserviços, desenvolvimento e operações (DevOps), baixo código/sem código, computação de borda, código aberto, operações bimodais, engenharia de Confiabilidade do Local (SRE) e quantidades crescentes de automação através de ferramentas de tecnologia da informação (TI) padrão, interface de programação de aplicações abertas (APIs) e inteligência artificial (IA), inteligência artificial generativa (GenAI) e aprendizado de máquina (ML). Sua linha abrangente de serviços é projetada para atender a todas as etapas do ciclo de vida de um provedor de serviços e inclui consultoria, entrega, engenharia de qualidade (testes), integração de sistemas, operações e serviços. serviços de rede, serviços orientados por experiên', 'Saint Louis, MO, United States', 29058);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CYN', 'STOCK', 'Cyngn Inc.', 'NCM', 'Technology', 'Software - Application', 'Cyngn Inc. is an autonomous vehicle (AV) technology company that is focused on addressing industrial uses for autonomous vehicles. The Company integrates its full-stack autonomous driving software, DriveMod, into vehicles manufactured by an original equipment manufacturer either via retrofit of existing vehicles or by integration directly into vehicle assembly. It designs the Enterprise Autonomy Suite (EAS) to be compatible with sensors and components from hardware technology providers and integrates its proprietary Autonomous Vehicle (AV) software to produce differentiated autonomous vehicles. EAS is a suite of technologies and tools that is divided into three categories: DriveMod, Cyngn Insight, and Cyngn Evolve. DriveMod is a modular industrial vehicle autonomous driving software. Cyngn Insight is a customer-facing tool suite for monitoring and managing AV fleets and generating/aggregating/analyzing data. Cyngn Evolve is an internal tool suite.', 'Menlo Park, CA, United States', 58);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BBAR', 'STOCK', 'Banco BBVA Argentina S.A.', 'NYQ', 'Financial Services', 'Banks - Regional', 'Banco Bbva Argentina SA, formerly known as BBVA French Bank, is an Argentina-based banking institution. Through its banking platform, the Bank provides a broad range of financial and non-financial services to both individuals and companies. It manages three business lines: Retail Banking, Small and Medium-Sized Companies and Corporate and Investment Banking (C&IB). Retail Banking offers checking and savings accounts, time deposits, credit cards, loans, mortgages, insurance and investment products, among others. Small and Medium-Sized Companies targets local private-sector companies providing financing products, factoring, checking accounts, time deposits, transactional and payroll services, insurance and investment products, among others. C&IB offers financial services to corporations and multinational companies, as well as global transaction services, global markets solutions, long term financing, among others. The Bank is active locally, mostly.', 'Buenos Aires, , Argentina', 6399);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BRCC', 'STOCK', 'BRC Inc.', 'NYQ', 'Consumer Defensive', 'Packaged Foods', 'BRC Inc. is a Veteran-founded and led coffee, energy drink, and media company. The Company purchases, roasts, and sells coffee, coffee accessories, and branded apparel through its online channels and business networks. Its product offerings include roast coffee, single-serve coffee, ready-to-drink (RTD) coffee, and Black Rifle Energy (RTD energy beverage). It offers Black Rifle branded apparel, coffee brewing equipment, and outdoor and lifestyle gear. The Company operates through three primary channels: Wholesale, Direct-to-Consumer (DTC), and Outposts. In its Wholesale channel, it sells packaged coffee and its RTD beverages through Food, Drug, and Mass (FDM) retailers such as Walmart, Sams Club, regional and national grocery chains, and convenience stores, such as 7-Eleven, Caseys General Store, and Circle K. Its Outposts channel offers brewed coffee and Black Rifle Coffee merchandise. The Company also develops and promotes online content for the purpose of growing its brands.', 'Salt Lake City, UT, United States', 551);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('DHT', 'STOCK', 'DHT Holdings, Inc.', 'NYQ', 'Energy', 'Oil & Gas Midstream', 'DHT Holdings, Inc. is an independent crude oil tanker company. The Company''s fleet trades internationally and consists of crude oil tankers in the Very Large Crude Carriers (VLCC) segment. Its primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. The Company operates its vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. Its principal activity is the ownership and operation of a fleet of crude oil carriers. It has approximately 28 vessels in operation. The fleet operates globally on international routes. The Company''s fleets are comprised of DHT Addax, DHT Antelope, DHT Gazelle, DHT Impala, DHT Appaloosa, DHT Mustang, DHT Bronco, DHT Colt, DHT Stallion, DHT Tiger, DHT Harrier, DHT Puma, DHT Panther, DHT Osprey, DHT Lion, DHT Leopard, DHT Jaguar, DHT Taiga, DHT Sundarbans, and DHT Scandinavia, among others.', 'Hamilton, , Bermuda', 924);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('DVAX', 'STOCK', 'Dynavax Technologies Corporation', 'NMS', 'Healthcare', 'Drug Manufacturers - Specialty & Generic', 'Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.', 'EmeryVille, CA, United States', 405);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('COR', 'STOCK', 'Cencora, Inc.', 'NYQ', 'Healthcare', 'Medical Distribution', 'A Cencora, Inc. É uma empresa global de serviços de fornecimento e distribuição de produtos farmacêuticos. A empresa ajuda os prestadores de cuidados de saúde e os fabricantes farmacêuticos e de biotecnologia a melhorar o acesso dos pacientes aos produtos e a melhorar o atendimento aos pacientes. A empresa opera através de dois segmentos: U.S. Healthcare Solutions e International Healthcare Solutions. O segmento de Soluções de Saúde dos EUA distribui uma oferta abrangente de marca, marca especializada e medicamentos genéricos, produtos de saúde de balcão, suprimentos e equipamentos de saúde em casa e serviços relacionados a uma variedade de prestadores de cuidados de saúde, incluindo hospitais de cuidados agudos e sistemas de saúde, farmácias de varejo independentes e em cadeia, farmácias de longo prazo e locais alternativos e outros clientes. O segmento International Healthcare Solutions é composto por empresas que se concentram em operações internacionais de atacado e serviços relaci', 'Conshohocken, PA, United States', 51000);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ALLR', 'STOCK', 'Allarity Therapeutics, Inc.', 'NCM', 'Healthcare', 'Biotechnology', 'Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.', 'Boston, MA, United States', 6);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ADTN', 'STOCK', 'ADTRAN Holdings, Inc.', 'NMS', 'Technology', 'Communication Equipment', 'ADTRAN Holdings, Inc. is a provider of open, disaggregated networking and communications solutions that enable voice, data, video and Internet communications across any network infrastructure. Its segments include Network Solutions, which offers hardware and software products, and Services & Support, which includes a portfolio of network design and implementation services, support services and cloud-hosted SaaS applications. The segments span across Subscriber Solutions, Access & Aggregation Solutions, and Optical Networking Solutions. Its Subscriber Solutions portfolio is used by service providers to terminate their access services infrastructure at the customer''s premises. The Access & Aggregation Solutions are solutions that are used by communications service providers to connect subscribers. Its Optical Networking Solutions are used by communications service providers, Internet content providers and large enterprises to securely interconnect metro and regional networks over fiber.', 'Huntsville, AL, United States', 3091);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BXSL', 'STOCK', 'Blackstone Secured Lending Fund', 'NYQ', 'Financial Services', 'Asset Management', 'Blackstone Secured Lending Fund is an externally managed, non-diversified, closed-end management investment company. The Companys investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. It invests at least 80% of its total assets in secured debt investments. The Company seeks to achieve its investment objectives primarily through originated loans and other securities, including syndicated loans, of private U.S. companies, typically in the form of first lien senior secured and unitranche loans (including first out/last out loans), and to a lesser extent, second lien, third lien, unsecured and subordinated loans and other debt and equity securities. It invests across various sectors, which include aerospace and defense, air freight and logistics, building products, commercial services and supplies, healthcare providers and services and others. The Company is externally managed by Blackstone Credit BDC Advisors LLC.', 'New York, NY, United States', NULL);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BR', 'STOCK', 'Broadridge Financial Solutions, Inc.', 'NYQ', 'Technology', 'Information Technology Services', 'Broadridge Financial Solutions, Inc. É uma empresa de tecnologia financeira. Ele fornece comunicações com investidores e soluções baseadas em tecnologia para bancos, corretores, gerentes de ativos e patrimônio, investidores e outros. Seu segmento de Soluções de Comunicação com Investidores (ICS) fornece Soluções Regulatórias, Soluções de Fundo Orientadas a Dados, Soluções de Emissor Corporativo e Soluções de Comunicação com o Cliente. O negócio de ICS envolve o processamento e distribuição de materiais proxy para investidores em títulos de capital e fundos mútuos, e a facilitação do processamento de votos relacionados. Seu segmento de Tecnologia e Operações Globais (GTO) fornece soluções que automatizam o ciclo de vida de transações frente a verso de ações, fundos mútuos, câmbio e derivativos negociados em bolsa, desde a captura e execução de pedidos até a confirmação de negociação, margem, reconciliações e outros. Ela também opera uma plataforma de processamento de transações dos Serv', 'Lake Success, NY, United States', 15000);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('AHH', 'STOCK', 'Armada Hoffler Properties, Inc.', 'NYQ', 'Real Estate', 'REIT - Diversified', 'Armada Hoffler Properties, Inc. is a vertically integrated, self-managed real estate investment trust (REIT). The Company is engaged in developing, building, acquiring, and managing office, retail and multifamily properties located primarily in the Mid-Atlantic and Southeastern United States. The Company operates through five segments: office real estate, retail real estate, multifamily real estate, general contracting & real estate services, and real estate financing. The Company''s general contracting, and real estate services business develops and builds properties for its own account and provides construction and development services to both related and third parties. The real estate financing segment includes the Company''s mezzanine loans and preferred equity investments on development projects. The Company also provides general construction and development services to third-party clients, in addition to developing and building properties to be placed in their stabilized portfoli', 'Virginia Beach, VA, United States', 148);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('DOV', 'STOCK', 'Dover Corporation', 'NYQ', 'Industrials', 'Specialty Industrial Machinery', 'A Dover Corporation é um fabricante global diversificado e fornecedor de soluções. Seu segmento de produtos de engenharia fornece uma gama de equipamentos, componentes, software, soluções e serviços para o pós-venda de veículos, aeroespacial e defesa, entre outros. Seu segmento de Energia Limpa e Abastecimento fornece componentes, equipamentos e soluções e serviços de software. Também projeta, fabrica e fornece sistemas de tubulação isolados a vácuo para uma variedade de gases liquefeitos, como nitrogênio, oxigênio, dióxido de carbono e outros gases industriais. O seu segmento de Imaging & Identification fornece marcação e codificação de precisão, rastreabilidade de produtos, proteção da marca e equipamento de impressão digital têxtil. Seu segmento de Bombas e Soluções de Processos fabrica bombas especiais e medidores de vazão, conetores de transferência de fluidos, componentes de precisão projetados, instrumentos e controles digitais. Seu segmento de Tecnologias Climate & Sustainabili', 'Downers Grove, IL, United States', 24000);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('AVXL', 'STOCK', 'Anavex Life Sciences Corp.', 'NMS', 'Healthcare', 'Biotechnology', 'Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimers disease, Parkinsons disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimers disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.', 'New York, NY, United States', 42);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ACHV', 'STOCK', 'Achieve Life Sciences, Inc.', 'NCM', 'Healthcare', 'Biotechnology', 'Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.', 'Bothell, WA, United States', 25);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BNZI', 'STOCK', 'Banzai International, Inc.', 'NCM', 'Technology', 'Software - Application', 'Banzai International, Inc. is a marketing technology company that provides artificial intelligence (AI)-enabled marketing and sales solutions for businesses of all sizes. The Company enables companies of all sizes to target, engage, and measure both new and existing customers more effectively. Its platform offers three software as a service (SaaS) products: Demio, Boost, and Reach. Demio is a user-friendly, browser-based webinar platform with extensive data and marketing features designed to help businesses engage with their audience through live events and on-demand, interactive video content. Boost is a tool utilized by customers to enhance participation in their Demio webinars. This tool allows registered attendees to promote Demio webinars on social media platforms. Customers use Reach to directly connect with their events target audience to increase registrations for their events. It also provides video hosting and marketing suite solutions for businesses through Vidello.', 'Bainbridge Island, WA, United States', 28);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('FLGC', 'STOCK', 'Flora Growth Corp.', 'NCM', 'Healthcare', 'Drug Manufacturers - Specialty & Generic', 'Flora Growth Corp. is a cannabis company that manufactures and distributes consumer packaged goods and distributes medicinal cannabis and pharmaceutical products. Its brand consists of JustCBD, Vessel, Melo, Haze, and Australian Vaporizers. JustCBD is a consumer-packaged goods brand with over 350 products, including cannabidiol gummies, topicals, tinctures, and vape products. JustCBD products are available for purchase in smoke and vape shops, clinics, spas, and pet stores, as well as other independent non-traditional retail channels. Vessel is the cannabis accessory and technology brand servicing the United States and Canada through direct-to-consumer and retail sales. Vessel''s products include cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops, and cannabis brands. Australian Vaporizers is an online retailer of vaporizers, hardware, and accessories in Australia.', 'Fort Lauderdale, FL, United States', 64);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CODI', 'STOCK', 'Compass Diversified', 'NYQ', 'Industrials', 'Conglomerates', 'Compass Diversified Holdings is engaged in owning and managing a diverse set of defensible, middle-market businesses across the branded consumer, industrial, healthcare, and critical outsourced services sectors. It categorizes its businesses into two separate groups: branded consumer businesses and industrial businesses. Its segments include 5.11 Acquisition Corp. (5.11), Boa Holdings Inc. (BOA), Lugano Holdings, Inc. (Lugano), Relentless Topco, Inc. (PrimaLoft), THP Topco, Inc., CBCP Products, LLC, AMTAC Holdings, LLC (Arnold), FFI Compass, Inc. (Altor Solutions or Altor) and SternoCandleLamp Holdings, Inc. (Sterno). 5.11 is a provider of purpose-built technical apparel and gear for law enforcement, firefighters, EMS, and military special operations as well as outdoor and adventure enthusiasts. BOA is a creator of the patented BOA Fit System, which consists of three integral parts: a micro-adjustable dial, high-tensile lightweight laces, and low friction lace guides.', 'Westport, CT, United States', 3340);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ANVS', 'STOCK', 'Annovis Bio, Inc.', 'NYQ', 'Healthcare', 'Biotechnology', 'Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimers disease (AD), and Parkinsons disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.', 'Malvern, PA, United States', 8);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('AHCO', 'STOCK', 'AdaptHealth Corp.', 'NCM', 'Healthcare', 'Medical Devices', 'AdaptHealth Corp. is a provider of patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home. Its product and service offerings include sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea; medical devices and supplies to patients for the treatment of diabetes, including continuous glucose monitors and insulin pumps; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. It operates in 50 states through its network of over 670 locations in 47 states.', 'Plymouth Meeting, PA, United States', 10500);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('AACT', 'STOCK', 'Ares Acquisition Corporation II', 'NYQ', 'Financial Services', 'Shell Companies', 'Ares Acquisition Corporation II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is not limited to a particular industry or geographic region for the purposes of consummating a business combination. The Company has neither engaged in any operations nor generated any revenue.', 'New York, NY, United States', NULL);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('ARCT', 'STOCK', 'Arcturus Therapeutics Holdings Inc.', 'NGM', 'Healthcare', 'Biotechnology', 'Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Companys pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company''s versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.', 'San Diego, CA, United States', 174);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CLDX', 'STOCK', 'Celldex Therapeutics, Inc.', 'NCM', 'Healthcare', 'Biotechnology', 'Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Companys bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.', 'Hampton, NJ, United States', 186);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('CR', 'STOCK', 'Crane Company', 'NYQ', 'Industrials', 'Specialty Industrial Machinery', 'Crane Company is an industrial manufacturing and technology company. The Company is a manufacturer of engineered components for mission-critical applications focused on the aerospace, defense, space and process flow industry end markets. Its segments include Aerospace & Electronics, and Process Flow Technologies. The Aerospace & Electronics segment supplies critical components and systems, including original equipment and aftermarket parts, primarily for the commercial aerospace, and the military aerospace, defense and space markets. The Process Flow Technologies segment is a provider of engineered fluid handling equipment for critical applications. The segment is comprised of Process Valves and Related Products, Pumps and Systems and Commercial Valves. The Company also designs and manufacturers multi-stage lubrication pumps and lubrication system components technology for critical aerospace and defense applications.', 'Stamford, CT, United States', 7500);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('BTCM', 'STOCK', 'BIT Mining Limited', 'NYQ', 'Technology', 'Information Technology Services', 'BIT Mining Ltd is a company principally engaged in cryptocurrency mining operation business. The Company mainly operates cryptocurrency mining machines for the sole purpose of mining cryptocurrencies (primarily bitcoin, and to a lesser extent ether).', 'Akron, OH, United States', 56);\nINSERT INTO assets_master (ticker, asset_type, name, exchange, sector, industry, business_description, headquarters, employees_count) VALUES ('EWZS', 'STOCK', 'iShares MSCI Brazil Small-Cap ETF', 'NGM', NULL, NULL, 'The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index designed to measure primarily the performance of equity securities of small capitalization companies listed on stock exchanges in Brazil.', '', NULL);\n